Health Care · Pharmaceutical Preparations

GLSI Greenwich LifeSciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 179978838 filings
Russell 2000

GLSI at a glance

Greenwich LifeSciences, Inc. (GLSI, SEC CIK 1799788) filed its latest 10-K annual report on June 1, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on December 18, 2025 and Form 4 insider filings as recently as July 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 12 institutional investment managers tracked by SignalX reported holding Greenwich LifeSciences, Inc. (GLSI) shares worth $22.9 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Patel Snehal on July 29, 2026 of 700 shares at $13.10 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
12 funds
$22.9M · −2 vs prior quarter
Latest 10-Q
Nov 16, 2026
Quarterly report

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, with no commercialization achieved
  • R&D expenses $5.45M, up 67% from $3.27M, driven by clinical expenses
  • G&A expenses $412,695, down 12% from $466,926, following option-grant expirations
  • Cash $5.90M vs $6.18M at December 31, 2025, operating cash use $9.62M
  • ATM financing net proceeds $9.34M, with 379,762 shares sold at $25.36 average price; additional capital required as losses continue

Risk Factors

  • No material changes from Form 10-K risk factors for year ended December 31, 2025

AI summary of the GLSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

SignalX for GLSI

Don't miss the next GLSI filing

  • Alerts as it files. A push when GLSI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GLSI, by share count.
  • Ask anything. An AI agent that reads every GLSI filing and answers with sources.

GLSI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Patel SnehalBuyJul 29, 2026$13.10
Patel SnehalBuyJul 28, 2026$13.59
Patel SnehalBuyJul 27, 2026$13.62
Patel SnehalBuyJul 24, 2026$12.88
Patel SnehalBuyJul 23, 2026$13.14
Patel SnehalBuyJan 13, 2026$29.83
Patel SnehalBuyJan 12, 2026$27.54
Patel SnehalBuyDec 31, 2025$21.36

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$9.3M-$16.0M-$19.4M
Net Income-$8.9M-$15.8M-$19.4M
Balance Sheet
Total Assets$7.0M$4.1M$6.2M
Equity$6.7M$2.5M$353K
ROE-132.7%-623.1%-5480.5%
Per Share
EPS$-0.69$-1.21$-1.43
Cash Flow
Operating CF-$6.5M-$7.3M-$9.9M

Source: XBRL data in Greenwich LifeSciences, Inc. (GLSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GLSI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GLSI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202612$22.9M
Q2 202614$28.7M
Q1 202616$27.7M
Q4 202514$19.6M
Q3 202516$9.3M
Q2 202516$8.5M
Q1 202512$4.7M
Q4 20248$5.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 108 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GLSI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 16, 2026Analysis
10-QAug 11, 2026Analysis
4Jul 30, 2026--
4Jul 29, 2026--
4Jul 27, 2026--
10-QJun 4, 2026Analysis
10-KJun 1, 2026-
4Jan 15, 2026-
4Jan 14, 2026-
4Jan 5, 2026-
4Jan 2, 2026-
4Dec 19, 2025-
8-KDec 18, 2025-
4Nov 28, 2025-
10-QNov 14, 2025Analysis
10-QAug 14, 2025-
10-QMay 20, 2025-
10-KApr 15, 2025-
10-QNov 14, 2024-
10-QAug 14, 2024-
10-QMay 20, 2024-
10-KApr 15, 2024-
10-QOct 19, 2023-
10-QAug 21, 2023-
10-QMay 22, 2023-

Related Health Care companies

All Health Care →

GLSI SEC filings: frequently asked questions

Which institutions hold GLSI stock?

As of September 30, 2026, the largest Greenwich LifeSciences, Inc. (GLSI) holders among the 13F filers tracked by SignalX were BlackRock ($9.2 million), Vanguard Capital Management LLC ($5.2 million), State Street Corp ($2.9 million), Vanguard Portfolio Management LLC ($1.7 million), Northern Trust ($1.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What are the latest GLSI SEC filings?

Greenwich LifeSciences, Inc. (GLSI) filed its latest 10-K annual report on June 1, 2026, a 10-Q quarterly report on November 16, 2026, an 8-K current report on December 18, 2025 and a Form 4 insider filing on July 30, 2026.

What is GLSI's SEC CIK number?

Greenwich LifeSciences, Inc. (GLSI)'s SEC Central Index Key (CIK) is 1799788. EDGAR lists every GLSI filing under that number.

Ask anything about GLSI

The research agent reads GLSI's filings, financials, insider trades and 13F holders, then answers with sources.